Delegation of the European Union to the

UN and other international organisations in Geneva

EU Statement: Standing Committee on the Law of Patents 29th Session (WIPO, Geneva, 3 - 6 December 2018) - Patents and Health Other related documents

Geneva, 11/12/2018 - 10:41, UNIQUE ID: 181211_12
Statements on behalf of the EU

EU Statement: Standing Committee on the Law of Patents 29th Session (WIPO, Geneva, 3 - 6 December 2018) - Patents and Health Other related documents

Chair,

 

  1. As stated previously, access to safe, effective, qualitative and affordable medicines and vaccines for all is a major challenge and a key Sustainable Development Goal that we all must support.

 

  1. Many aspects of the health system play an important role to ensure accessibility and affordability of medicines. This includes incentives to research and innovation, but also the availability of qualified health workers, the provision of affordable medicines as well as the adequate financing of the sector and others.

 

  1. A number of exceptions and limitations already ease access to patented inventions in the EU. Examples include the Bolar exemption and the Regulation on compulsory licensing of patents relating to the manufacture of pharmaceutical products for export to countries with public health problems, that was swiftly developed and adopted in 2006 by the EU, although this measure only became binding in 2017. This topic is appropriately addressed under Exceptions and Limitations.

 

  1. As far as the mandate of the SCP and WIPO is concerned we would also like to recall that we cannot go beyond our mandate and that we need to continue to reflect a balanced approach, taking into account the various factors of relevance to patents and health.

 

  1. Intellectual Property rights such as patents incentivize innovation, leading to new and improved treatments.

 

  1. The EU and its Member States thank the Secretariat for organizing the half-day conference on publicly accessible databases on patent information status and data, on medicines and vaccines, as well as the sharing session of experiences by practitioners on negotiating licensing agreements. These are topics that we find very promising, as they can lead to increased transparency, smoother licensing, and reduced costs – to the benefit of all. We welcome interesting discussions of these highly important topics.

 

Thank you.

Editorial Sections: